{
    "clinical_study": {
        "@rank": "112638", 
        "arm_group": {
            "arm_group_label": "Transplantation of CD3/CD19 depleted stem cells", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive a minimum dosage of 10x10E6/kg bodyweight CD3/CD19 depleted CD34+ stem cells. Maximum dosage of residual T cells will be 1x10E5/kg BW"
        }, 
        "brief_summary": {
            "textblock": "Feasibility and toxicity of haploidentical transplantation of CD3/CD19 depleted stem cells\n      in combination with a toxicity reduced conditioning regimen or with standard conditioning\n      regimens according to underlying disease."
        }, 
        "brief_title": "Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Leukemias", 
            "Aplastic Anemia", 
            "Childhood Solid Tumor"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Anemia, Aplastic", 
                "Leukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with primary refractory or relapsed disease (including relapse after\n             previous SCT and active disease)\n\n          -  AML in complete remission of refractory\n\n          -  MDS RAEB-t/secondary AML\n\n          -  ALL\n\n          -  CML\n\n          -  Non-Hodgkin Lymphoma / Hodgkin Lymphoma\n\n          -  non malignant diseases (aplastic anemia, thalassemia, SCID)\n\n          -  relapsed Neuroblastoma\n\n          -  relapsed soft tissue sarcoma (Rhabdomyosarcoma, Ewing sarcoma, PNET\n\n          -  soft tissue sarcoma with primary bone metastases or bone marrow\n\n          -  in whom no matched donor was available,\n\n        Exclusion Criteria:\n\n          -  < 6 months after previous HSCT\n\n          -  active cerebral seizure conditions\n\n          -  massive progression of leukemias or solid tumours before planned trp.\n\n          -  left ventricular ejection fraction <25%\n\n          -  creatinine clearance <40ml/min before conditioning\n\n          -  respiratory insufficiency with oxygen demand or DLCO <30%\n\n          -  Bilirubin >4mg/dl, GOT/GPT >400\n\n          -  severe infection (HIV, Aspergillosis)\n\n          -  pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "25 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919866", 
            "org_study_id": "1075/01 PEI"
        }, 
        "intervention": {
            "arm_group_label": "Transplantation of CD3/CD19 depleted stem cells", 
            "intervention_name": "Transplantation of CD3/CD19 depleted stem cells", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 8, 2013", 
        "location": [
            {
                "contact": {
                    "email": "christian.urban@medunigraz.at", 
                    "last_name": "Christian Urban, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "8036"
                    }, 
                    "name": "University Children's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "christine.mauz-koerholz@medizin.uni-halle", 
                    "last_name": "Christine Mauz-K\u00f6rholz, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Halle", 
                        "country": "Germany", 
                        "zip": "6120"
                    }, 
                    "name": "University Children's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sauer.martin@mh-hannover.de", 
                    "last_name": "Martin Sauer, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "zip": "30625"
                    }, 
                    "name": "Medizinische Hochschule Zentrum f\u00fcr Kinderheilkunde"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bernd.gruhn@med.uni-jena.de", 
                    "last_name": "Bernd Gruhn, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Jena", 
                        "country": "Germany", 
                        "zip": "7745"
                    }, 
                    "name": "University Children's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tuebingen", 
                        "country": "Germany", 
                        "zip": "72076"
                    }, 
                    "name": "University Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Peter Lang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Germany"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Haploidentical Stem Cell Transplantation With CD3/CD19 Depleted Stem Cells in Pediatric Patients With Refractory Hematological and Oncological Diseases", 
        "overall_contact": {
            "email": "peter.lang@med.uni-tuebingen.de", 
            "last_name": "Peter Lang, MD", 
            "phone": "+4970712981386"
        }, 
        "overall_contact_backup": {
            "email": "rupert.handgretinger@med.uni-tuebingen.de", 
            "last_name": "Rupert Handgretinger, MD", 
            "phone": "+4970712984744"
        }, 
        "overall_official": {
            "affiliation": "University Children\u2019s Hospital Tuebingen", 
            "last_name": "Peter Lang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "engraftment rate will be evaluated by leukocyte counts in peripheral blood . Definition of engraftment: >500 neutrophiles/\u00b5l blood. Transplant related mortality will be evaluated at day 100 and day 365 post transplant", 
            "measure": "Engraftment rate and transplant related mortality", 
            "safety_issue": "Yes", 
            "time_frame": "365 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919866"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Children's Hospital Tuebingen", 
            "investigator_full_name": "Peter Lang", 
            "investigator_title": "Prof. Dr. med.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Incidence of acute and chronic GvHD will be evaluated according to Glucksberg criteria. Immune recovery will be evaluated by flow cytometry. Percentages and numbers of T, B and NK cells will be measured weekly until day 100, afterwards on day 180 and 365.", 
            "measure": "Graft versus Host disease and speed of immune reconstitution", 
            "safety_issue": "Yes", 
            "time_frame": "365 days"
        }, 
        "source": "University Children\u2019s Hospital Tuebingen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Children\u2019s Hospital Tuebingen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2004", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}